CT demonstrates afocal inflammatory process in theposterior sphenoid sinus on the left, with developmental dehiscence of the lateral wallof the optic nerve canal (arrow) allowing the inflammatory process to extendinto theoptic canal and apexof theorbit (A). Contrast-enhanced axialMRI reveals enhancement of theinflammatory process extendingfrom theposterior sphenoid sinusinto theorbital apexand around the optic nerve (arrow). Inflammation of the medial rectus muscle and periorbital area isalso noted(B). Coronal MR images at thelevel of theorbital apex(arrow) (e) and at thelevel of theproximal optic nerve (arrow) (D) reveal marked inflammatory enhancement in theoptic sheath of theoptic nerve.
CT demonstrates afocal inflammatory process in theposterior sphenoid sinus on the left, with developmental dehiscence of the lateral wallof the optic nerve canal (arrow) allowing the inflammatory process to extendinto theoptic canal and apexof theorbit (A). Contrast-enhanced axialMRI reveals enhancement of theinflammatory process extendingfrom theposterior sphenoid sinusinto theorbital apexand around the optic nerve (arrow). Inflammation of the medial rectus muscle and periorbital area isalso noted (B) . Coronal MR images at thelevel of theorbital apex(arrow) (e) and at thelevel of theproximal optic nerve (arrow) (D) reveal marked inflammatory enhancement in theoptic sheath of theoptic nerve.
The optic nerve and other important structures in the anterior skull base can be involved in chronic sphenoidal sinus disease.1,2 An unusual bony anomaly of the sphenoid sinus in the case presented here led to blindness.Y A 51-year-old man with a history of immunosup-pressive therapy for kidneylliver transplantation presented with a worsening headache of 3 months' duration that led to vision loss in the left eye. Three months earlier, he had received antibiotic treatment for sinus disease with no follow-up. During the current admission, computed tomogra- 
5.2Glaucoma and Cataracts
Nasal and inhaled corticosteroids may result inthe development ofglaucoma and cataracts. Therefore, close monitoring iswarranted inpatients with achange invision orwith ahistory ofincreased intraocular pressure, glaucoma, orcataracts.
5.3Hypersensitivity
ZETONNA Nasal Aerosol is contraindicated inpatients with aknown hypersensitivity to ciclesonide orany ofthe ingredients ofZETONNA Nasal Aerosol. Cases ofhypersensitivity reactions following administration of ciclesonide with manifestations such as angioedema, with swelling ofthe lips, tongue and pharynx, have been reported.
5.4Immunosuppression
Patients who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, forexample, can have amore serious oreven fatal course insusceptible children oradults using corticosteroids. Inchildren oradults who have not had these diseases orbeen properly immunized, particular care should be taken toavoid exposure. How the dose, route, and duration ofcorticosteroid administration affect the risk ofdeveloping adisseminated infection isnot known. The contribution ofthe underlying disease orprior corticosteroid treatment tothe risk isalso not known. If apatient isexposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If apatient isexposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts forcomplete VZIG and IG prescribing information). If chickenpox develops, treatment with antiviral agents may be considered.
Corticosteroids should be used with caution, if atall, inpatients with active orquiescent tuberculosis infections ofthe respiratory tract; orinpatients with untreated local orsystemic fungal orbacterial infections; systemic viral orparasitic infections; orocular herpes simplex because ofthe potential forworsening ofthese infections. 
Adults and Adolescents 12Years ofAge and Older in Short-Term
(2-6 weeks) Trials: Inthree short-term trials and the first6 weeks ofone long-term trial, conducted inthe US, 884 patients with ahistory ofseasonal orperennial allergic rhinitis were treated with ZETONNA Nasal Aerosol 74 mcg daily. Adverse reactions did not differ appreciably based on age, gender, orrace. The table below displays reactions that occurred with an incidence ofatleast 2.0% and more frequently with ZETONNA Nasal Aerosol 74 mcg than with placebo inseasonal orperennial allergic rhinitis clinical trials of2to6weeks duration.
DRUG INTERACTIONS
In vitro studies and clinical pharmacology studies suggested that desciclesonide has no potential formetabolic drug interactions orprotein bindingbased drug interactions [see Clinical Pharmacology (12.3) in the full prescribing information]. Inadrug interaction study, co-a?m.in.istration of orally inhaled ciclesonide and oral ketoconazole, apotent Inhlb.ltor of . cytochrome P450 3M, increased the exp~sure (AUC)~f des-c.l cl esom~e by approximately 3.6-fold atsteady state, while levels ofciclesonlde remained unchanged. Erythromycin, a moderate inhibitor of cytochrome P450 3M, had no effect on the pharmacokinetics ofeither des-ciclesonide orerythromycin following oral inhalation ofciclesonide [see Clinical Pharmacology (12.3) 
8.4Pediatric Use
The safety and effectiveness forseasonal and perennial allergic rhinitis in children 12years ofage and older have been established. The safety and efficacy ofZETONNA Nasal Aerosol fortreatment ofthe symptoms ofseasonal and perennial allergic rhinitis inpatients 11 years ofage and younger have not been established.
Controlled clinical trials have shown that intranasal corticosteroids may cause a reduction ingrowth velocity in pediatric patients. This effect has been observed inthe absence oflaboratory evidence ofhypothalamicpituitary-adrenal (HPA)-axis suppression, suggesting that growth velocity is a more sensitive indicator ofsystemic corticosteroid exposure in pediatric patients than some commonly used tests ofHPA-axis function. The longterm effects ofthis reduction ingrowth velocity associated with intranasal corticosteroids, including the impact on final adult height, are unknown. The potential for"catch-up" growth following discontinuation oftreatment with intranasal corticosteroids has not been adequately studied. The growth ofpediatric patients receiving intranasal corticosteroids, including ZETONNA Nasal Aerosol, should be monitored routinely (e.g., via stadiometry). A 52-week, multi-center, double-blind, randomized, placebo-controlled parallelgroup trial was conducted to assess the effect of orally inhaled ciclesonide (ALVESCO~Inhalation Aerosol) on growth rate in609 pediatric patients with mild persistent asthma, aged 5 to8.5 years. Treatment groups included orally inhaled ciclesonide 40 mcg or160 mcg orplacebo given once daily. Growth was measured by stadiometer height during the baseline, treatment and follow-up periods. The primary comparison was the difference ingrowth rates between ciclesonide 40 and 160 mcg and placebo groups. Conclusions cannot be drawn from this trial because compliance could not be assured. Ciclesonide blood levels were also not measured during the one-year treatment period. There was no difference inefficacy measures between the placebo and the orally inhaled ciclesonide (ALVESCO@ Inhalation Aerosol) groups. 
Long-Term (26·Week Double-Blind and 26-Week Open-Label) Safety Trial:
Inone 26-week double-blind, placebo-controlled safety trial that included 1110 adult and adolescent patients with perennial allergic rhinitis, additional adverse reactions, with an incidence ofatleast 2%, that occurred more frequently with ZETONNA Nasal Aerosol than with placebo were upper respiratory tract infection, urinary tract infection, oropharyngeal pain, nasal mucosal/septum disorders, viral upper respiratory tract infection, cough, influenza, bronchitis, streptococcal pharyngitis, muscle strain, and nausea. Nasal discomfort (5.7%) and epistaxis (11.4%) were also more frequent in the 26-week safety trial compared to clinical trials 2to 6 weeks induration. Nasal mucosal/septum disorders and cough demonstrated a dose response. Discontinuations due to adverse reactions were higher inZETONNA Nasal Aerosol treated patients compared to placebo treated patients and demonstrated adose response. Local adverse reactions leading to discontinuation were also higher inZETONNA Nasal Aerosol 74 mcg treated patients (1.7%) compared to placebo treated patients (0.7%). The only local adverse reaction leading to discontinuation that occurred inZETONNA Nasal Aerosol treated patients and was not observed inthe 2-to 6-week trials was upper respiratory tract infection. Atotal of824 patients with perennial allergic rhinitis who completed the 26-week double-blind trial enrolled into an open-label extension and received ZETONNA Nasal Aerosol 148 mcg for26 weeks. Additional adverse reactions, observed with an incidence ofatleast 2% were sinusitis, nasopharyngitis, and back pain. Atotal of4 nasal septal ulcerations were also reported inthe 26-week open-label extension. There were no reports ofnasal septal perforations inthe long-term safety trial.
6.2Post-marketing Experience
Additional adverse reactions have been identified during worldwide postmarketing use with other formulations of ciclesonide, ALVESCO~Inhalation Aerosol and OMNARIS~Nasal Spray. Because these reactions are reported voluntarily from a population ofuncertain size, it is not always possible to reliably estimate their frequency orestablish acausal relationship to drug exposure.
ALVESCO~Inhalation Aerosol: immediate ordelayed hypersensitivity reactions such as angioedema with swelling ofthe lips, tongue, and pharynx. phy (CT) of the head was performed, showing a focal inflammatory process on the left side of the sphenoid sinus with an unusual dehiscence of the medial portion of the proximal optic canal (figure, A). Magnetic resonance imaging (MRI) of the orbits was also performed, confirming the focal inflammatory process that extended through the dehiscence into the left optic nerve and apex of the left orbit (figure, B-D). Urgent functional endoscopic sinus surgery with left sphenoidectomy and sinus drainage was performed. The patient improved clinically after surgery; however, he developed changes in his mental status over the next few days. An MRI revealed an acute ischemic infarction in the left basal ganglia. A CT angiogram revealed the compromised left cavernous sinus and cavernous portion of the internal carotid artery and, subsequently, cavernous sinus thrombosis, confirmed clinically and on imaging.
Although it is uncommon to find an isolated focal inflammatory process in the sphenoid sinus compro-420 • www.entjournal.com mising the optic nerve and posterior orbits,i.s occasionally complications-including acute vision losscan occur in cases with an unusual developmental bony dehiscence of the lateral wall of the optic nerve canal, predisposing the infection to extend into the optic nerve and orbital apex.
